Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Besançon, Besançon, France; Laboratoire Associé au Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, Besançon, France; Chrono-environnement, Université Bourgogne-Franche Comté, Besançon, France.
Laboratoire Associé au Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, Besançon, France.
Int J Antimicrob Agents. 2023 Sep;62(3):106917. doi: 10.1016/j.ijantimicag.2023.106917. Epub 2023 Jul 8.
Cefiderocol has an excellent in vitro activity on clinical strains of Pseudomonas aeruginosa (P. aeruginosa). However, the resistance of some isolates has been associated with the production of some β-lactamases. Whether some acquired extended-spectrum oxacillinases (ES-OXA) common in this species may compromise the susceptibility of P. aeruginosa to cefiderocol has not been evaluated so far.
Eighteen genes encoding OXA belonging to the major subgroups identified in P. aeruginosa OXA-1 (n = 3); - 2 (n = 5); - 10 (n = 8), and - 46 (n = 2) were cloned into pUCP24 shuttle vector and transferred into reference strain PAO1.
Although production of the OXA-1 subgroup enzymes did not alter cefiderocol MICs, the β-lactamases of OXA-2, OXA-46, and four variants of the OXA-10 subgroup resulted in an 8-fold to 32-fold decrease in susceptibility in the PAO1 background. Interestingly, point mutations Ala149Pro and Asp150Gly in OXA-2 subgroup, Trp154Cys and Gly157Asp in OXA-10 subgroup (all located in the Ω loop), and the duplication of a Thr206 and a Gly207 in the β5-β6 loop of OXA-10 subgroup were related to decreased susceptibility to cefiderocol. We also showed that some ES-OXA, including the most frequent ES-OXA in P. aeruginosa strains, OXA-19 (derived from OXA-10 subgroup), significantly compromised activity of cefiderocol in addition to ceftazidime, ceftolozane/tazobactam, and ceftazidime/avibactam in clinical strains.
This work shows that several ES-OXA have a significant effect on cefiderocol susceptibility. Of concern are the Trp154Cys and Gly157Asp mutations that occur in some of these β-lactamases, as they are associated with a decreased activity of the most recent cephalosporins introduced to combat P. aeruginosa infections.
头孢地尔可对临床分离的铜绿假单胞菌(P. aeruginosa)具有极好的体外活性。然而,一些分离株的耐药性与某些β-内酰胺酶的产生有关。目前尚未评估该物种中一些常见的获得性扩展谱头孢菌素酶(ES-OXA)是否会影响铜绿假单胞菌对头孢地尔的敏感性。
将编码属于铜绿假单胞菌 OXA-1(n=3);-2(n=5);-10(n=8)和-46(n=2)主要亚群的 18 个 OXA 基因克隆到 pUCP24 穿梭载体中,并转移到参考菌株 PAO1 中。
尽管 OXA-1 亚群酶的产生并未改变头孢地尔的 MICs,但 OXA-2、OXA-46 和 OXA-10 亚群的四种变体β-内酰胺酶导致 PAO1 背景下的敏感性降低了 8 倍至 32 倍。有趣的是,位于Ω环中的 OXA-2 亚群中的 Ala149Pro 和 Asp150Gly 点突变,OXA-10 亚群中的 Trp154Cys 和 Gly157Asp 点突变(均位于Ω环中)以及 OXA-10 亚群β5-β6 环中的 Thr206 和 Gly207 重复与对头孢地尔的敏感性降低有关。我们还表明,一些 ES-OXA,包括铜绿假单胞菌菌株中最常见的 ES-OXA,OXA-19(源自 OXA-10 亚群),除了头孢他啶、头孢噻肟/他唑巴坦和头孢他啶/阿维巴坦外,还显著降低了临床菌株中头孢地尔的活性。
这项工作表明,几种 ES-OXA 对头孢地尔的敏感性有显著影响。令人担忧的是这些β-内酰胺酶中存在的 Trp154Cys 和 Gly157Asp 突变,因为它们与最近用于治疗铜绿假单胞菌感染的头孢菌素的活性降低有关。